Sold as Arduan. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Pipecuronium Bromide (sold as Arduan), first approved Jun 26, 1990, with 0 new uses approved and 0 published complete response letters.
| Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane AnesthesiaNeuromuscular Blocking Agents, Residual Neuromuscular Block · Tamas Vegh, MD | Phase 4 | Not yet recruiting | Jun 29, 2025 |
| Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol AnesthesiaNeuromuscular Blocking Agents, Residual Neuromuscular Block · Tamas Vegh, MD | Phase 4 | Active, not recruiting | Jun 29, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 26, 1990 | ArduanNDA 19638 · New molecular entity | Organon USA Inc | 5 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
